香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2627） 內幕消息： (1) 延遲刊發截至2025年12月31日止年度的年度業績公告； (2) 董事會會議延期；及 (3) 暫停買賣 本公告乃由江蘇中慧元通生物科技股份有限公司（「本公司」或「中慧元通生物科 技」，連同其附屬公司統稱「本集團」）根據香港聯合交易所有限公司（「聯交所」） 證券上市規則（「上市規則」）第13.09(2)(a)條及第13.49(3)(i)條以及香港法例第571 章證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市規則）作出。 茲提述本公司日期為2026年3月19日的公告（「該公告」），內容有關本公司原定於 2026年3月31日（星期二）舉行董事（「董事」）會（「董事會」）會議，藉以（其中包 括）考慮及批准本集團截至2025年12月31 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 江蘇中慧元通生物科技股份有限公司 執行董事、董事長兼總經理 安有才先生 香港，2026年3月19日 於本公告日期，董事會成員包括：(i)執行董事安有才先生、李潤香女士及何一鳴 先生；(ii)非執行董事程千文先生、于建林先生及杜沐先生；及(iii)獨立非執行董 事李向明先生、李建軍先生及陳乘貝先生。 （股份代號：2627） 董事會會議日期 江蘇中慧元通生物科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹 此宣佈，本公司將於2026年3月31日（星期二）舉行董事會會議，藉以（其中包括） 考慮及批准本公司及其附屬公司截至2025年12月31日止財政年度之經審核全年業 績及其刊發，以及考慮派發末期股息之建議（如有）。 承董事會命 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會認為，香港沃森是海外業務拓展的先行者，擁有豐富的國際化運營經驗。 透過本次合作，本公司將藉助香港沃森生物多年深耕積累的海外市場資源及成熟 完善的分銷網絡，加快推動產品進軍東南亞、拉丁美洲、中東及南半球其他地區 市場。 1 （股份代號：2627） 自願性公告 訂立戰略合作協議 本公告由江蘇中慧元通生物科技股份有限公司（「本公司」或「中慧生物」，連同其 附屬公司，統稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集 團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司與沃森生物香港有限公司 （「香港沃森」）訂立有關亞單位流感疫苗海外市場拓展的戰略合作協議（「戰略合作 協議」）。 戰略合作協議 根據戰略合作協議，雙方將就本集團研發產品的海外市場註冊、銷售及商業化開 展深度合作。本次海外拓展的核心產品為本集團自主研發的三價亞單位流感疫苗 （惠爾康欣3）（「該產品」）。該 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2627） 自願性公告 mRNA猴痘疫苗獲美國FDA的IND許可 本公告由江蘇中慧元通生物科技股份有限公司（「本公司」或「中慧生物」，連同其 附屬公司，統稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集 團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於美國（「美國」），美國食品藥物 監督管理局（「FDA」）已許可本集團自主研發的在研mRNA猴痘疫苗的臨床研究用 新藥（「IND」）申請。 猴痘由猴痘病毒引發，而猴痘病毒是痘病毒科正痘病毒屬的一員。該病毒屬包括 廣泛的病毒群，包含牛痘病毒、天花病毒及鼠痘病毒等。在臨床前研究中，與中 國所用的天花病毒減毒活疫苗天壇株相比，我們的在研mRNA猴痘疫苗引發的猴 痘中和抗體水平明顯更高，而且 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇中慧元通生物科技股份有限公司 本月底法定/註冊股本總額： RMB 393,442,600 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02627 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 296,361,845 | RMB | | 1 RMB | | 296,361,845 | | 增加 / 減少 (-) | | | 0 | | | RMB | | ...

Core Viewpoint - Zhonghui Biopharmaceutical has announced a significant positive outlook for 2025, projecting annual revenue between 446 million to 493 million yuan, representing a year-on-year growth of 71.8% to 89.9%, while expecting a net loss reduction of approximately 23.9% to 39.3% [1][2] Group 1: Financial Performance - The company expects to achieve substantial revenue growth in 2025, with a projected increase of 71.8% to 89.9% compared to the previous year [1][2] - The anticipated net loss for the period is estimated to be between 157 million to 197 million yuan, indicating a significant narrowing of losses [1][2] - The stock price has increased over 30% since the beginning of the year, reflecting strong market interest and investor confidence in the company's long-term value [1][2] Group 2: Product Development and Commercialization - The core product, the four-valent influenza virus subunit vaccine Hui Er Kang Xin®, has achieved a 100% product approval rate and has expanded its sales network to cover 30 provinces in China [2][3] - The vaccine has passed preliminary review for inclusion in the 2025 National Commercial Health Insurance innovative drug list, which is expected to enhance its market penetration [2][3] - The company is focusing on expanding the target population for its core product, with clinical approvals for a vaccine aimed at the elderly and ongoing research for pregnant women [3][4] Group 3: Market Positioning and Competitive Advantage - The four-valent and three-valent vaccines are positioned to meet the evolving market demand for more precise and comprehensive influenza protection [5][6] - The Hui Er Kang Xin® vaccine addresses the industry pain point of dosage reduction and limited protection for infants, offering a solution with a higher antigen purity [3][4] - The company is also developing a pipeline of innovative vaccines, including a freeze-dried rabies vaccine and mRNA-based vaccines, to strengthen its market position [6][7] Group 4: Future Outlook - Zhonghui Biopharmaceutical has successfully entered the Hong Kong Stock Connect program, which is expected to enhance liquidity and valuation potential [8] - The company is at a critical turning point with the potential for annual profit and accelerated commercialization of innovative products, further increasing investment certainty [2][8]

Core Viewpoint - The company, Zhonghui Biopharmaceutical-B, has announced significant positive developments, including a projected revenue increase of 71.8% to 89.9% for 2025, alongside a notable reduction in net losses, indicating a strong commercial validation of its innovative vaccine products [1][2]. Group 1: Financial Performance - The company expects to achieve annual revenue between 446 million to 493 million yuan in 2025, reflecting a year-on-year growth of 71.8% to 89.9% [1]. - The anticipated net loss for the same period is projected to be approximately 157 million to 197 million yuan, which represents a significant narrowing of losses by 23.9% to 39.3% compared to the previous year [1]. Group 2: Market Position and Stock Performance - The company's stock has seen a remarkable increase of over 360% since its IPO, with a recent peak price of 59.90 HKD, indicating strong market interest and investor confidence [2]. - The inclusion of Zhonghui Biopharmaceutical in the new round of Hong Kong Stock Connect has heightened market attention towards the company [1][2]. Group 3: Product Development and Commercialization - The core product, the four-valent influenza virus subunit vaccine, has achieved a 100% product approval rate since its launch in September 2023, with rapid expansion across 30 provinces and numerous vaccination centers [2][3]. - The company is focusing on expanding its core product's applicability, including a vaccine for the elderly and ongoing research for pregnant women, which could fill existing gaps in influenza immunization [3][4]. Group 4: Innovation and R&D Pipeline - Zhonghui Biopharmaceutical is actively developing a diverse pipeline of vaccines, including a freeze-dried rabies vaccine and various mRNA vaccines targeting multiple diseases, indicating a robust commitment to innovation [6][7]. - The rabies vaccine, which is currently in phase III clinical trials, is expected to become a significant growth driver following the influenza vaccine [7]. Group 5: Strategic Outlook - The company is positioned to benefit from the dual advantages of enhanced vaccination rates and technological upgrades in the industry, which could lead to increased investment certainty [5][6]. - The successful entry into the Hong Kong Stock Connect is anticipated to provide additional liquidity and valuation upside for the company [8].

2.数字化精准营销决策市场销售策略与实施，大模型销售数据实时可视化分析、目标区块划分及沙盘推 演纠偏、精准敏捷的差异化政策，加上大规模人群上市后评价、孕妇、肾病综合征患者等特殊人群学术 研究，以及省市区到终端的学术推广服务覆盖准入区域的终端市场和消费者。更具针对性的数据驱动营 销方式提高了营销费用的使用效率，在支撑收入增长的同时，有助于降低销售费用; 3.公司2025年的产品发货相较于2024年进一步增加覆盖了232个疾控中心以及2,563个接种门诊，因此， 公司的接种渠道相较去年为消费者产品提供了更多区域的选择，直接推动了营业收入的增长; 4.在研发费用持续投入的基础上，公司降本增效取得初步成效，虽然2025年本集团上市费用大幅度增 加，但收入增长与成本管控收紧的综合效应使得2025财年净亏损进一步收窄。 中慧生物-B(02627)发布公告，集团预期于2025财年录得约人民币4.46亿元至人民币4.93亿元的营业收 入，较截至2024年12月31日止年度的人民币2.6亿元营业收入增加约71.8%至89.9%，并预期于2025财年 录得约人民币1.57亿元至人民币1.97亿元的净亏损，较截至2024年12月3 ...

Core Viewpoint - Zhonghui Biotech-B (02627.HK) anticipates significant revenue growth for the fiscal year ending December 31, 2025, alongside a reduction in net loss compared to the previous fiscal year [1] Financial Projections - The company expects to achieve revenue between approximately RMB 446 million and RMB 493 million for the fiscal year 2025, representing an increase of about 71.8% to 89.9% compared to the revenue of RMB 259.6 million for the fiscal year ending December 31, 2024 [1] - The projected net loss for the fiscal year 2025 is expected to be between approximately RMB 157 million and RMB 197 million, which indicates a decrease of about 23.9% to 39.3% from the net loss of RMB 258.7 million for the fiscal year ending December 31, 2024 [1]

Core Viewpoint - Zhonghui Biotech-B (02627) expects to achieve approximately RMB 446 million to RMB 493 million in revenue for the fiscal year 2025, representing an increase of about 71.8% to 89.9% compared to RMB 260 million in revenue for the year ending December 31, 2024. The company anticipates a net loss of approximately RMB 157 million to RMB 197 million for the same period, a reduction of about 23.9% to 39.3% from a net loss of RMB 259 million for the previous year [1] Group 1 - The increase in revenue and reduction in net loss are primarily attributed to the continuous enhancement of the company's quality management system, which ensures a 100% product quality approval rate, thereby lowering sales costs [1] - The implementation of digital precision marketing strategies, including real-time visualization of sales data and targeted marketing policies, has improved the efficiency of marketing expenses while supporting revenue growth [1] - The company has expanded its product delivery to cover 232 disease control centers and 2,563 vaccination clinics, providing more regional options for consumers and directly driving revenue growth [1] Group 2 - Despite a significant increase in listing expenses for 2025, the combined effect of revenue growth and tightened cost control has led to a further narrowing of the net loss for the fiscal year [1]